1 0 1 0 1 O
site 2 6 2 6 O
of 7 9 7 9 O
measurable 10 20 10 20 O
disease 21 28 21 28 O
greater 29 36 29 36 O
than 37 41 37 41 O
( 42 43 42 43 O
> 43 44 43 44 O
) 44 45 44 45 O
1 46 47 46 47 B-lower_bound
centimeter 48 58 48 58 I-lower_bound
( 59 60 59 60 I-lower_bound
cm 60 62 60 62 I-lower_bound
) 62 63 62 63 I-lower_bound
in 64 66 64 66 O
the 67 70 67 70 O
longest 71 78 71 78 O
diameter 79 87 79 87 O

1 0 1 88 89 B-lower_bound
to 2 4 90 92 O
30 5 7 93 95 B-upper_bound
years 8 13 96 101 I-upper_bound
of 14 16 102 104 O
age 17 20 105 108 B-age

1 0 1 109 110 O
to 2 4 111 113 O
less 5 9 114 118 O
than 10 14 119 123 O
( 15 16 124 125 O
< 16 17 125 126 O
) 17 18 126 127 O
18 19 21 128 130 B-upper_bound
years 22 27 131 136 I-upper_bound
of 28 30 137 139 O
age 31 34 140 143 B-age

< 0 1 144 145 O
18 1 3 145 147 B-upper_bound
years 4 9 148 153 I-upper_bound
of 10 12 154 156 O
age 13 16 157 160 B-age

A 0 1 161 162 O
diagnosis 2 11 163 172 O
of 12 14 173 175 O
post 15 19 176 180 B-chronic_disease
- 19 20 180 181 I-chronic_disease
transplant 20 30 181 191 I-chronic_disease
lymphoproliferative 31 50 192 211 I-chronic_disease
disease 51 58 212 219 I-chronic_disease
( 59 60 220 221 I-chronic_disease
PTLD 60 64 221 225 I-chronic_disease
) 64 65 225 226 I-chronic_disease

Adolescent 0 10 227 237 O
women 11 16 238 243 B-gender
/ 16 17 243 244 O
young 17 22 244 249 O
women 23 28 250 255 O
of 29 31 256 258 O
childbearing 32 44 259 271 O
potential 45 54 272 281 O
must 55 59 282 286 O
have 60 64 287 291 O
a 65 66 292 293 O
negative 67 75 294 302 B-pregnancy
highly 76 82 303 309 I-pregnancy
sensitive 83 92 310 319 I-pregnancy
serum 93 98 320 325 I-pregnancy
or 99 101 326 328 I-pregnancy
urine 102 107 329 334 I-pregnancy
beta 108 112 335 339 I-pregnancy
- 112 113 339 340 I-pregnancy
human 113 118 340 345 I-pregnancy
chorionic 119 128 346 355 I-pregnancy
gonadotropin 129 141 356 368 I-pregnancy
( 142 143 369 370 I-pregnancy
beta 143 147 370 374 I-pregnancy
- 147 148 374 375 I-pregnancy
hCG 148 151 375 378 I-pregnancy
) 151 152 378 379 I-pregnancy
pregnancy 153 162 380 389 I-pregnancy
test 163 167 390 394 O
at 168 170 395 397 O
Screening 171 180 398 407 O
before 181 187 408 414 O
enrollment 188 198 415 425 O
/ 198 199 425 426 O
randomization 199 212 426 439 O

Adolescent 0 10 440 450 O
/ 10 11 450 451 O
young 11 16 451 456 O
women 17 22 457 462 B-gender
who 23 26 463 466 O
are 27 30 467 470 O
pregnant 31 39 471 479 B-pregnancy
or 40 42 480 482 O
breastfeeding 43 56 483 496 O
are 57 60 497 500 O
ineligible 61 71 501 511 O
for 72 75 512 515 O
this 76 80 516 520 O
study 81 86 521 526 O

Participants 0 12 527 539 O
must 13 17 540 544 O
be 18 20 545 547 O
in 21 23 548 550 O
first 24 29 551 556 O
recurrence 30 40 557 567 O
or 41 43 568 570 O
have 44 48 571 575 O
disease 49 56 576 583 O
that 57 61 584 588 O
is 62 64 589 591 O
primarily 65 74 592 601 O
refractory 75 85 602 612 O
to 86 88 613 615 O
conventional 89 101 616 628 B-treatment
therapy 102 109 629 636 I-treatment

Participants 0 12 637 649 O
who 13 16 650 653 O
are 17 20 654 657 O
within 21 27 658 664 O
6 28 29 665 666 B-upper_bound
months 30 36 667 673 I-upper_bound
of 37 39 674 676 O
an 40 42 677 679 O
allogeneic 43 53 680 690 B-treatment
bone 54 58 691 695 I-treatment
marrow 59 65 696 702 I-treatment
transplant 66 76 703 713 I-treatment

Participants 0 12 714 726 O
who 13 16 727 730 O
have 17 21 731 735 O
had 22 25 736 739 O
prior 26 31 740 745 O
exposure 32 40 746 754 O
to 41 43 755 757 O
ibrutinib 44 53 758 767 B-treatment

Participants 0 12 768 780 O
with 13 17 781 785 O
any 18 21 786 789 O
condition 22 31 790 799 O
that 32 36 800 804 O
could 37 42 805 810 O
interfere 43 52 811 820 O
with 53 57 821 825 O
the 58 61 826 829 O
absorption 62 72 830 840 O
or 73 75 841 843 O
metabolism 76 86 844 854 O
of 87 89 855 857 O
ibrutinib 90 99 858 867 B-treatment
including 100 109 868 877 O
malabsorption 110 123 878 891 B-chronic_disease
syndrome 124 132 892 900 I-chronic_disease
, 132 133 900 901 O
disease 134 141 902 909 O
significantly 142 155 910 923 O
affecting 156 165 924 933 O
gastrointestinal 166 182 934 950 O
function 183 191 951 959 O
, 191 192 959 960 O
or 193 195 961 963 O
resection 196 205 964 973 B-treatment
of 206 208 974 976 I-treatment
the 209 212 977 980 I-treatment
stomach 213 220 981 988 I-treatment
or 221 223 989 991 I-treatment
small 224 229 992 997 I-treatment
bowel 230 235 998 1003 I-treatment

Participants 0 12 1004 1016 O
with 13 17 1017 1021 O
inherited 18 27 1022 1031 O
or 28 30 1032 1034 O
acquired 31 39 1035 1043 O
bleeding 40 48 1044 1052 B-chronic_disease
disorders 49 58 1053 1062 I-chronic_disease

Participants 0 12 1063 1075 O
with 13 17 1076 1080 O
known 18 23 1081 1086 O
allergies 24 33 1087 1096 B-allergy_name
, 33 34 1096 1097 O
hypersensitivity 35 51 1098 1114 B-allergy_name
, 51 52 1114 1115 O
or 53 55 1116 1118 O
intolerance 56 67 1119 1130 O
to 68 70 1131 1133 O
ibrutinib 71 80 1134 1143 B-allergy_name
or 81 83 1144 1146 O
its 84 87 1147 1150 O
excipients 88 98 1151 1161 O
( 99 100 1162 1163 O
refer 100 105 1163 1168 O
to 106 108 1169 1171 O
Investigator 109 121 1172 1184 O
's 121 123 1184 1186 O
Brochure 124 132 1187 1195 O
) 132 133 1195 1196 O

Participants 0 12 1197 1209 O
with 13 17 1210 1214 O
lansky 18 24 1215 1221 B-clinical_variable
- 24 25 1221 1222 I-clinical_variable
Karnofsky 25 34 1222 1231 I-clinical_variable
score 35 40 1232 1237 I-clinical_variable
of 41 43 1238 1240 O
greater 44 51 1241 1248 O
than 52 56 1249 1253 O
or 57 59 1254 1256 O
equal 60 65 1257 1262 O
to 66 68 1263 1265 O
( 69 70 1266 1267 O
> 70 71 1267 1268 O
=) 71 73 1268 1270 O
50 74 76 1271 1273 B-lower_bound

Participants 0 12 1274 1286 O
with 13 17 1287 1291 O
ongoing 18 25 1292 1299 O
anticoagulation 26 41 1300 1315 B-treatment
treatment 42 51 1316 1325 I-treatment
with 52 56 1326 1330 O
warfarin 57 65 1331 1339 B-treatment
or 66 68 1340 1342 O
equivalent 69 79 1343 1353 O
vitamin 80 87 1354 1361 O
K 88 89 1362 1363 O
antagonists 90 101 1364 1375 O
( 102 103 1376 1377 O
example 103 110 1377 1384 O
phenprocoumon 111 124 1385 1398 O
) 124 125 1398 1399 O

has 0 3 1400 1403 O
taken 4 9 1404 1409 O
any 10 13 1410 1413 O
disallowed 14 24 1414 1424 O
therapies 25 34 1425 1434 B-treatment
as 35 37 1435 1437 O
noted 38 43 1438 1443 O
in 44 46 1444 1446 O
Section 47 54 1447 1454 O
8.2 55 58 1455 1458 O

